Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 Manufacturing Scale Comparability Sub-study
NCT05038618Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Medigen Biotechnology. Started Aug 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05038618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038618.